# Abramson Cancer Center Support Grant

> **NIH NIH P30** · UNIVERSITY OF PENNSYLVANIA · 2020 · $150,078

## Abstract

The goal of the Abramson Cancer Center (ACC) of the University of Pennsylvania is to bring together more
than 310 members to transform the paradigm of patient-centered cancer care and cancer control by integrating
high impact Programs of basic, clinical, and population-based research, fostering pioneering scientific
discoveries, and facilitating the translation of these discoveries into clinical practice. In doing so, the ACC
builds upon the great clinical cancer care at renowned hospitals of the University of Pennsylvania and the
Children’s Hospital of the Philadelphia. The ACC continues to build on its significant historical strengths in
basic cancer biology, translational immunotherapy, and population science research. By leveraging the
infusion of new Institutional resources and significant philanthropic resources, the ACC will continue to
innovate to reduce the burden of cancer in our catchment area during the next project period and will seek to:
(1) Accelerate and expand its leadership in adoptive cellular immunotherapy, combination immune
checkpoint therapies, and vaccine development for both prevention and treatment of cancers.
(2) Increase translation of cancer basic biology through the philanthropic and Institutionally supported ACC
Translational Centers of Excellence that integrate basic, translational and clinical scientists from the ACC
Programs to impact on the prevention, detection, and treatment of specific types of cancers that afflict our
catchment area.
(3) Accelerate precision cancer medicine through novel Molecular Imaging, the Center for Personalized
Diagnostics, the Molecular Tumor Board, and the Circulating Tumor Material Developing Core, which
were implemented in the past project period, and the implementation of the Center for Rare Cancers and
Personalized Therapy in the next project period.
(4) Innovate means to understand, prevent, and treat therapy-resistant cancers by incorporating genomics,
epigenomics, informatics and research in cancer metabolism, which is frequently re-wired in resistance to
targeted therapies.
(5) Lead population-based research through recruitment and research tools in genetics and complex traits
with an emphasis on cancer epidemiology. Implement projects in cancer molecular epidemiology among
patients of African descent and accelerate our Outreach Program to increase research relevant to our
catchment area.
(6) Launch a new Brain and Behavior Change initiative and harness new tools from cognitive neurosciences
to control cancer by modulating behaviors that predispose to smoking or contribute to obesity. Lead in
Toxicology and Environmental Carcinogenesis to understand environmental toxins and impact the health
of patients with mesothelioma in our catchment area.

## Key facts

- **NIH application ID:** 10243006
- **Project number:** 3P30CA016520-44S7
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** Robert H. Vonderheide
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $150,078
- **Award type:** 3
- **Project period:** 1997-01-15 → 2020-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10243006

## Citation

> US National Institutes of Health, RePORTER application 10243006, Abramson Cancer Center Support Grant (3P30CA016520-44S7). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10243006. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*